Dr. Jennifer Chheda, a partner in the Firm's Intellectual Property Practice resident in the New York Office, was named to the Women We Admire "Top 50 Women Leaders in Law" list. The editors note that the 2023 group is representative of women lawyers who are "instrumental in leading their organizations by offering unparalleled legal guidance, championing the rights of their clients, and steadfastly upholding the tenets of justice."
Dr. Chheda has more than 20 years of experience developing, implementing, and managing worldwide patent portfolios covering commercial biologics and pharmaceuticals as well as products in development, including clinical candidates. She obtained a Ph.D. in Microbiology and a M.Sc. in Microbiology from New York University as well as a B.S. in Molecular and Cellular Biology from the University of Connecticut. She has worked with pioneers developing vaccines, such as a universal influenza virus vaccine, and virus-based cancer vaccines.
Dr. Chheda has evaluated and prosecuted patent portfolios relating to enzyme replacement therapy, RNA therapeutics, gene therapy, antibodies, antibody drug conjugates, and cell-based therapies (for example, CAR-T cells). In addition, her practice includes patentability, invalidity, noninfringement, freedom-to-operate, and inventorship analyses; conducting due diligence for clients; providing strategic advice to clients regarding post-grant proceedings and invalidity actions; and drafting and negotiating intellectual property agreements.